Disparity between angiographic regression and clinical event rates with hydrophobic statins

Lancet

Volumn 359, Issue 9324, 2002, Pages 2195-2198

  Ichihara, Kazuo ^a   Satoh, Kumi ^a  

^a HOKKAIDO INSTITUTE OF TECHNOLOGY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CERIVASTATIN; CHOLESTEROL; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PLACEBO; PRAVASTATIN; SIMVASTATIN; UBIQUINONE;

ANGIOCARDIOGRAPHY; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DRUG DISTRIBUTION; DRUG EFFECT; DRUG POTENCY; HEART MUSCLE CELL; HUMAN; PRIORITY JOURNAL; PROPHYLAXIS; REMISSION; RHABDOMYOLYSIS; SHORT SURVEY;

EID: 0037157593     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(02)09098-0     Document Type: Note

References (25)

1. Regulation of the mevalonic pathway
2. Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): Reduction in atherosclerosis progression and clinical events
3. Pravastatin, lipids, and atherosclerosis in the carotid arteries (PLAC-II)
4. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: The Regression Growth Evaluation Statin Study (REGRESS)
5. Effect of simvastatin on coronary atheroma: The Multicentre Anti-Atheroma Study (MAAS)
6. Coronary angiographic changes with lovastatin therapy: The Monitored Atherosclerosis Regression Study (MARS)
7. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography: The Canadian Coronary Atherosclerosis Intervention Trial (CCAIT)
8. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations: Lipoprotein and coronary atherosclerosis study (LCAS)
9. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
10. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
11. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
12. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
13. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS
14. Beneficial effects of pravastatin (±colestyramin/niacin) initiated immediately after a coronary event: The randomized Lipid-Coronary Artery Disease (L-CAD) study
15. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACL study - A randomized controlled trial
16. Fluvastatin in acute myocardial infarction: Effects on early and late ischemia and events - The FLORIDA trial
17. In vitro and in vivo synthesis of dlichol and other main mevalonate products in various organs of the rat
18. Possible involvement of 3-hydroxymethylglutaryl-CoA reductase in determining side-chain length of ubiquinone in rat heart
19. 4-Hydroxybenzoate: Polyprenyl transferase and the prenylation of 4-aminobenzoate in mammalian tissues
20. Influences of pravastatin and simvastatin, HMG-CoA reductase inhibitors, on myocardial stunning in dogs
21. Lipophilic HMG-CoA reductase inhibitors increase myocardial stunning in dogs
22. Effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on mitochondrial respiration in ischemic dog hearts
23. Current concepts in cardiovascular pathology: The role of LDL cholesterol in plaque rupture and stabilization
24. Mechanism of action of fibrates on lipid and lipoprotein metabolism
25. Statin-induced inhibition of the Rho-signaling pathway activates PPARa and induces HDL apoA-I